The Board of Directors of MAB has approved the listing of ATRYS HEALTH on the Growth Companies segment of this market, following a thorough review of all the information presented by the company and after the favourable assessment report on its listing issued by MAB’s Coordination and Admission Committee
The company is scheduled to start trading next Friday, 22 July. It will be the twelfth company to join MAB in 2016.Together with the listing, the company has carried out a €4.5 million capital increase, bringing its initial market capitalisation to €16.5 million. The starting price will be €1.48 per share.
The company’s trading code will be ATRY and trading will be through a price setting mechanism which will match buy and sell orders by means of two daily auction periods or “fixings”, at 12 hrs and at 16 hrs.
NORGESTION is acting as Registered Adviser and Banco Sabadell as Liquidity Provider.
ATRYS HEALTH is a company concerned with the provision of diagnostic services and medical treatments, combining precision technical diagnosis in pathological and molecular anatomy and online image diagnosis, through its own multi-specialist technological platform with new treatments of radiation oncology.
The Market Status informs through quick and easy-to-read notices on incidents affecting the Equity, Derivatives and Fixed Income markets as well as Indices and financial systems operated by BME.
If an issue occurs, the message "TRADING" will change to "MARKET ISSUE" to reflect that a market event has occurred. By clicking on the Issue of the published alert it will be possible to access the information and intraday updates associated with this incident, which will be published immediately.
Note: BME will use its discretion to assign the severity of an incident